RedHill Biopharma (RDHL) Change in Receivables (2016 - 2022)
Historic Change in Receivables for RedHill Biopharma (RDHL) over the last 7 years, with Q4 2022 value amounting to -$4.2 million.
- RedHill Biopharma's Change in Receivables fell 922.28% to -$4.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $1.7 million, marking a year-over-year increase of 9377.78%. This contributed to the annual value of $52000.0 for FY2024, which is 9983.71% down from last year.
- RedHill Biopharma's Change in Receivables amounted to -$4.2 million in Q4 2022, which was down 922.28% from -$501000.0 recorded in Q3 2022.
- RedHill Biopharma's 5-year Change in Receivables high stood at $5.7 million for Q1 2022, and its period low was -$4.2 million during Q4 2022.
- For the 5-year period, RedHill Biopharma's Change in Receivables averaged around -$92250.0, with its median value being -$240000.0 (2018).
- Per our database at Business Quant, RedHill Biopharma's Change in Receivables crashed by 104255.32% in 2020 and then skyrocketed by 116766.47% in 2021.
- Quarter analysis of 5 years shows RedHill Biopharma's Change in Receivables stood at $474000.0 in 2018, then crashed by 80.17% to $94000.0 in 2019, then plummeted by 1042.55% to -$886000.0 in 2020, then tumbled by 335.67% to -$3.9 million in 2021, then decreased by 9.22% to -$4.2 million in 2022.
- Its last three reported values are -$4.2 million in Q4 2022, -$501000.0 for Q3 2022, and $718000.0 during Q2 2022.